ATE400574T1 - Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase - Google Patents

Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase

Info

Publication number
ATE400574T1
ATE400574T1 AT05815826T AT05815826T ATE400574T1 AT E400574 T1 ATE400574 T1 AT E400574T1 AT 05815826 T AT05815826 T AT 05815826T AT 05815826 T AT05815826 T AT 05815826T AT E400574 T1 ATE400574 T1 AT E400574T1
Authority
AT
Austria
Prior art keywords
pyrrolopyridine
acid amide
glycogen phosphorylase
carbonic acid
amide derivative
Prior art date
Application number
AT05815826T
Other languages
English (en)
Inventor
Jozsef Repasi
Andras Szabo
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Application granted granted Critical
Publication of ATE400574T1 publication Critical patent/ATE400574T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT05815826T 2004-12-02 2005-12-02 Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase ATE400574T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63246304P 2004-12-02 2004-12-02

Publications (1)

Publication Number Publication Date
ATE400574T1 true ATE400574T1 (de) 2008-07-15

Family

ID=35735250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815826T ATE400574T1 (de) 2004-12-02 2005-12-02 Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase

Country Status (11)

Country Link
US (1) US8664397B2 (de)
EP (1) EP1819704B1 (de)
JP (1) JP2008521874A (de)
AT (1) ATE400574T1 (de)
DE (1) DE602005008099D1 (de)
DK (1) DK1819704T3 (de)
ES (1) ES2309822T3 (de)
HK (1) HK1107984A1 (de)
PL (1) PL1819704T3 (de)
PT (1) PT1819704E (de)
WO (1) WO2006059165A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
CN103626837B (zh) * 2013-09-30 2016-11-23 承德医学院 含生物可裂解二肽的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN103626826B (zh) * 2013-09-30 2015-10-21 承德医学院 含偶氮键的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN103819486B (zh) * 2014-01-27 2016-08-17 承德医学院 标记血清糖原磷酸化酶浓度水平的光亲和标记探针分子、其制备方法及医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
BRPI0410445B1 (pt) 2003-05-21 2017-11-28 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase

Also Published As

Publication number Publication date
JP2008521874A (ja) 2008-06-26
EP1819704B1 (de) 2008-07-09
DE602005008099D1 (de) 2008-08-21
PL1819704T3 (pl) 2008-12-31
WO2006059165A1 (en) 2006-06-08
ES2309822T3 (es) 2008-12-16
EP1819704A1 (de) 2007-08-22
US8664397B2 (en) 2014-03-04
US20080293761A1 (en) 2008-11-27
PT1819704E (pt) 2008-10-06
HK1107984A1 (en) 2008-04-25
DK1819704T3 (da) 2008-10-20

Similar Documents

Publication Publication Date Title
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2008012490A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
WO2006093547A3 (en) Novel lipoxygenase inhibitors
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ATE400574T1 (de) Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase
SG158091A1 (en) Imidazoazepinone compounds
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
EA200800203A1 (ru) Замещенные изотопами ингибиторы протонного насоса

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1819704

Country of ref document: EP